Please login to the form below

Not currently logged in
Email:
Password:

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

BMSThe UK's National Institute for Health and Care Excellence has again not recommended Bristol-Myers Squibb's lung cancer immunotherapy Opdivo for use on the NHS.

 But the cost-effectiveness body has offered the company the opportunity for a limited trial through the newly-reformed Cancer Drugs Fund.

 Concluding a year-long discussion with BMS and NHS England, NICE said in draft guidance that Opdivo (nivolumab) is not cost-effective for all patients with squamous and non-squamous advanced non-small cell lung cancer (NSCLC).

 The watchdog has, however, acknowledged a particular benefit in NSCLC patients with PD-L1 status and has requested that BMS prepare its case for the inclusion of Opdivo in the CDF to gather more information on its cost-effectiveness in this patient population.

 Commenting on the decision, Benjamin Hickey, general manager of BMS UK & Ireland, said that the firm is "extremely disappointed for the majority of lung cancer patients for whom this NICE guidance could deny a potential life-line".

 He added: "We strongly disagree with the notion that nivolumab treatment should be restricted to around one third of patients because this is inconsistent with the clinical evidence."

 A PD-1 inhibitor, Opdivo targets PD-L1 proteins on the surface of cells, which are responsible for reducing the effectiveness of immune cells. Cancerous lung cells have more PD-L1 than normal cells, preventing the body from attacking the tumour.

Data from the CheckMate-057 clinical trials showed that Opdivo extended the survival period for NSCLC patients with PD-L1 status by seven months more than those with less PD-L1, but overall, 39% of Opdivo-treated patients were still alive after 18 months compared with just 23% of patients treated with the standard Taxoterre (doxetaxel) chemotherapy.

However, at a minimum of £73,500 per quality-adjusted life year (QALY) for squamous NSCLC and over £150,000 per QALY for non-squamous NSCLC, the cost of the drug far exceeds the usual incremental cost-effectiveness ratio (ICER) sought by NICE.

Hickey added: "We continue to be open to finding a solution for all advanced lung cancer patients who could potentially benefit from nivolumab."

Article by
Rebecca Clifford

14th October 2016

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...

Infographics